AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BLTE

Scholl Hendrik Peter sold $83K of BLTE (indirect holdings)

Scholl Hendrik Peter (Chief Medical Officer) sold 500 indirectly-held shares of BELITE BIO, INC (BLTE) at an average of $165.32 ($163.62–$170.02) across 8 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Scholl Hendrik Peter
Published Oct 5, 2026, 11:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Bearish
high confidence
Mentioned
$BLTE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTEBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a lack of confidence, potentially nudging the stock lower.

02

Market read

A modest insider sell by a senior executive; likely limited but negative short‑term impact.

03

What to watch

Potential upcoming clinical data releases or partnership news may offset the negative signal.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filing by BELITE BIO's Chief Medical Officer discloses an open‑market sale of 500 shares.

Company-level read

Ticker impact

$BLTEBearishHigh confidence
Context

Chief Medical Officer sold 500 shares for $82,658 via a 10b5-1 plan, reducing his stake to 14,500 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 filing is a primary source; the sale size is modest but the CMO role adds significance.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are common and usually company‑specific.

Regional

No regional effect; the filing is U.S.‑focused.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • company
    BELITE BIO, INC

    Biotech firm focused on oncology therapeutics.

  • insider
    Scholl Hendrik Peter

    Chief Medical Officer of BELITE BIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

$BLTEHighAI 8/10

Belite Bio Says Nasdaq Approved Move to Higher Listing Tier

Belite Bio (BLTE) announced its approval to move to Nasdaq's Global Select Market, starting Oct. 19. The company expects increased institutional investor attention and improved liquidity. Belite Bio is seeking approval for tinlarebant, its lead treatment for Stargardt disease, with the FDA setting a Feb. 12, 2027, action date.

econotimes.com
$BLTEMed

Belite Bio stock price target maintained at $245 by H.C. Wainwright

H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.

investing.com
$BLTEMedAI 8/10

Belite Bio submits drug applications in Singapore, UK, Switzerland

Belite Bio (BLTE) submitted Marketing Authorization Applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company also filed applications in the US and Japan, with the US application receiving Priority Review. Tinlarebant met its primary endpoint in a Phase 3 trial and has received several regulatory designations.

investing.com